Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium

New England Journal of Medicine

Volumn 342, Issue 6, 2000, Pages 374-380

  Gerhardt, Andrea ^a   Scharf, Rüdiger Eberhard ^a   Beckmann, Matthias Wilhelm ^a   Struve, Sabine ^a   Bender, Hans Georg ^a   Pillny, Michael ^a   Sandmann, Wilhelm ^a   Zotz, Rainer Bernd ^a,b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTITHROMBIN; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; RISK ASSESSMENT; RISK FACTOR; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; FACTOR V; FEMALE; GENETIC MARKERS; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POINT MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREVALENCE; PROTHROMBIN; PUERPERAL DISORDERS; RECURRENCE; RISK; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 0034628535     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200002103420602     Document Type: Article

References (27)

1. Prevention of venous thrombosis and pulmonary embolism: NIH Consensus Development. JAMA 1986;256:744-9.
2. Kierkegaard A. Incidence and diagnosis of deep vein thrombosis associated with pregnancy. Acta Obstet Gynecol Scand 1983;62:239-43.
3. Treffers PE, Huidekoper BL, Weenink GH, Kloosterman GJ. Epidemiological observations of thrombo-embolic disease during pregnancy and in the puerperium, in 56,022 women. Int J Gynaecol Obstet 1983;21:327-31.
4. Rutherford S, Montoro M, McGehee W, Strong T. Thromboembolic disease associated with pregnancy: an 11-year review. Am J Obstet Gynecol 1991;164:Suppl:286. abstract.
5. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995;173:210-3.
6. Greer IA. Haemostasis and thrombosis in pregnancy. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and thrombosis. Vol. 2. Edinburgh, Scotland: Churchill Livingstone, 1994:987-1015.
7. Dahlbäck B, Stenflo J. A natural anticoagulant pathway: protein C, S, C4b-binding protein and thrombomodulin. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and thrombosis. Vol. 1. Edinburgh, Scotland: Churchill Livingstone, 1994:671-98.
8. Dizon-Townson DS, Nelson LM, Jang H, Varner MW, Ward K. The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis. Am J Obstet Gynecol 1997;176:883-6.
9. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
10. Bokarewa MI, Bremme K, Blombäck M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996;92: 473-8.
11. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
12. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
13. Margaglione M, D'Andrea G, d'Addedda M, et al. The methylenetetrahydrofolate reducuse TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation. Thromb Haemost 1998;79:907-11.
14. Eichinger S, Stümpflen A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998;80:566-9.
15. Kluijtmans LAJ, den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998;79:254-8.
16. Hallak M, Senderowicz J, Cassel A, et al. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol 1997;176:889-93.
17. Kniemeyer HW, Merckle R, Stühmeier K, Sandmann W. Chirurgische Therapie der akuten und cmbolisierenden tiefen Beinvenenthrombose -Indikation, Technisches Prinzip, Ergebnisse. Klin Wochenschr 1990;68: 1208-16.
18. Kniemeyer HW, Sandmann W. Chirurgische Therapie der tiefen Venenthrombose in Schwangerschaft und Wochenbett. Gynakologe 1990;23:91-6.
19. Kolvenbach R, Grabitz K, Distler W, Eichwede F, Sandmann W. Die embolisierende Bein- und Beckenvenenthrombose in der Spät-Schwangerschaft: Indikation für ein simultanes, interdisziplinäres Vorgehen. Gynakologe 1991;24:305-6.
20. Kniemeyer HW, Sandmann W, Schwindt C, Grabitz K, Torsello G, Stuhmeier K. Thrombectomy with arteriovenous fistula for embolizing deep venous thrombosis: an alternative therapy for prevention of recurrent pulmonary embolism. Clin Invest 1993;72:40-5.
21. Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol 1996;143:1257-65.
22. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7.
23. Zotz RB, Maruhn-Debowski B, Scharf RE. Mutation in the gene coding for coagulation factor V and resistance to activated protein C: detection of the genetic mutation by oligonucleotide ligation assay using a semiautomated system. Thromb Haemost 1996;76:53-5.
24. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CRM. The prothrombin gene G20210A variant: prevalence in a U.K. anti-coagulant clinic population. Br J Haematol 1997;98:353-5.
25. Hillarp A, Zöller B, Svensson PJ, Dahlbäck B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 1997:78: 990-2.
26. Leroyer C, Mercier B, Oger E, et al. Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost 1998;80:49-51.
27. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998;338:1793-7.